Closure Medical adopts rights plan:
This article was originally published in Clinica
Closure Medical, which develops and manufactures adhesive products based on its proprietary cyanoacrylate technology for wound closure, has put in place a shareholder rights plan. The plan is activated if a third party acquires 15% or more of the company or announces a tender amount for that amount. "We believe that the plan protects stockholder interests in the event that the company is confronted with coercive or unfair takeover tactics, including offers that do not treat all stockholder interests fairly or do not maximise the value of the company," said Robert Toni, president and CEO of the Raleigh, North Carolina-based company.
You may also be interested in...
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”
After almost a year as CEO of Centrient, Rex Clements reflects on the company’s experiences operating amid a pandemic that has underlined the importance of a diversified supply chain, while also highlighting the firm’s sustainable manufacturing initiatives and calling for non-price criteria to be taken into account by procurement processes, in an exclusive interview with Generics Bulletin.